Genetic variation in PTX3 is associated with susceptibility to community-acquired pneumonia in adults: a retrospective case control study

Yingqi Xiao  
Sun Yat-sen Memorial Hospital

Shiyi Bu  
Sun Yat-sen Memorial Hospital, Department of Pulmonary and Critical Care Medicine

Tiantian Tang  
Sun Yat-sen Memorial Hospital, Department of Pulmonary and Critical Care Medicine

Qiaojun Zeng  
Sun Yat-sen Memorial Hospital, Department of Pulmonary and Critical Care Medicine

Biru Huang  
Sun Yat-sen Memorial Hospital, Department of Pulmonary and Critical Care Medicine

Yumeng Dai  
Sun Yat-sen Memorial Hospital, Department of Pulmonary and Critical Care Medicine

Zixin Wei  
Sun Yat-sen Memorial Hospital, Department of Pulmonary and Critical Care Medicine

Linjie Huang  
Sun Yat-sen Memorial Hospital, Department of Pulmonary and Critical Care Medicine

Shanping Jiang (jiangshp@mail.sysu.edu.cn)  
Sun Yat-sen Memorial Hospital

Research

Keywords: Community-acquired pneumonia, innate immunity, Pentraxin 3, single nucleotide polymorphisms

DOI: https://doi.org/10.21203/rs.3.rs-40415/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

Background

Evidence indicates that single nucleoid polymorphisms (SNPs) of key molecules in innate immunity are related to clinical outcome of community-acquired pneumonia (CAP). Pentraxin 3 (PTX3) is a member of the acute-phase reactants superfamily and plays an important role against various diseases. The purpose of the current study was to assess the association between PTX 3 SNP and the risk of CAP.

Methods

This is a retrospective case-control study. Patients who were diagnosed with CAP between January 2018 to December 2019 in the Department of Pulmonary and Critical Care Medicine at Sun Yat-sen Memorial Hospital were included as CAP group. Then CAP cases were matched 1:1 by gender with non-infectious hospitalized patients during the same time. We detected the genotypes, allele frequencies and haplotype distributions of three SNPs within PTX3 gene (rs2305619, rs3816527, and rs1840680) by polymerase chain reaction sequencing in CAP group and control group, and compared their associations with the risk of CAP.

Results

Three SNPs in both groups were consist with Hardy-Weinberg equilibrium. A strong linkage disequilibrium was detected between any pair of rs2305619, rs3816527 and rs1840680 (|D'|≥0.85). There were no differences of rs2305619 and rs3816527 in genotypic distribution and haplotype frequency between CAP group and control group. However, we identified that SNP rs1840680 AA homozygote was associated with a lower risk of CAP in adults (OR, 0.32; 95% CI, 0.11-0.91; \(p = 0.03\)).

Conclusions

Our findings suggested that PTX3 single nucleoid polymorphism was associated with the risk of CAP in adults.

Background

As a common and deadly condition, community-acquired pneumonia (CAP) is increasingly prevalent and remains a significant health problem. Most patients can be cured after antimicrobial treatment, but some individuals may develop acute lung injury and even die from septic shock after rapid disease progression [1]. In America, 77% of CAP hospitalized patients improved, 20% didn’t change, and 3% had worsened. Mortality at 30 days was 6% for those who improved, 34% for those who failed, and 34% for those with non-resolving pneumonia. Mortality at 1 year was 23%, 52%, and 51% [2]. In recent years, reports have shown that genetic factors have a certain influence on the susceptibility to infection with pathogens. It has been found that gene polymorphisms of tumor necrosis factor receptor (TNFR), interleukin-1 (IL-1),
interferon regulatory factor-5 (IRF-5) and other key molecules in the inflammatory response pathway may be related to the susceptibility, severity and prognosis of CAP [3–7].

Pentraxin-3 (PTX3), a member of the family of long pentraxins, is an acute phase reactive protein. As a key player in innate immunity and inflammation, PTX3 is critical to host defense against microbial infection including bacteria, fungi and viruses [8]. Differing from short-chain pentameric factors mainly derived from the liver such as C-reactive protein (CRP), PTX3 is a marker for systemic inflammation which is produced rapidly by various cells under inflammatory or stress conditions [9]. Serum PTX3 is found to be present at low levels in health status, and significantly increase in patients who suffer from infectious diseases or tissue injury. Some studies suggested that compared with other biomarkers such as CRP, the concentration of PTX3 in serum can deliver better reflection of the inflammatory status, early assessment of disease severity and prediction of prognosis [10–11].

The human PTX3 gene, localizing on human chromosome 3 band q25, is organized in three exons separated by two introns [8]. Three single nucleotide polymorphisms (SNPs) in PTX3 (rs2305619, rs3816527 and rs1840680) have been demonstrated functional significance. Previous studies have found that PTX3 gene polymorphisms are associated with several infectious diseases, such as tuberculosis in West Africans, Pseudomonas aeruginosa in patients with pulmonary cystic fibrosis, and invasive aspergillosis in patients with chronic obstructive pulmonary disease (COPD) or after hematopoietic stem cell transplantation [12–15].

However, the association between PTX3 genetic variation and the susceptibility to community-acquired pneumonia is still unknown. Therefore, the aim of the present study was to assess the association between three PTX3 SNPs (rs2305619, rs3816527 and rs1840680) and the CAP occurrence.

**Methods**

We conducted a retrospective case-control study in the Department of Pulmonary and Critical Care Medicine of Sun Yat-sen Memorial Hospital, a university teaching hospital. This study protocol was approved by the Ethics Committees of Sun Yat-sen Memorial Hospital (SYSEC-KY-KS-2020-005). Written informed consent was obtained from each individual that participated in this study or their authorized relatives.

We obtained the medical records of all inpatients in the Department of Pulmonary and Critical Care Medicine of Sun Yat-sen Memorial Hospital from January 2018 and December 2019. A total of 178 participants were enrolled in the present study. Among them, 88 cases were diagnosed with community-acquired pneumonia according to the Chinese Thoracic Society (CTS) guideline [16] and defined as CAP group, while the remaining 90 cases were gender-matched controls without infectious diseases and defined as control group. Exclusion criteria were as follows: (1) age less than 18 years; (2) evidence that strongly indicates the presence of active tuberculosis or pulmonary fungal diseases; (3) a history of malignancies undergoing chemotherapy; (3) a documentary medication of long-term corticosteroids or immunosuppressive agents; and (4) a history of acquired immune deficiency syndrome.
Based on the previous study [12–15], we chose three single nucleotide polymorphisms (SNPs; rs2305619, rs3816527, and rs1840680) of PTX3. Genomic DNA was extracted from patient peripheral blood by a DNA extraction kit (Shanghai Generay Biotech, China). The primers and MGB probes (Sango Biotech, Shanghai, China) were designed in Beacon Designer software based on the SNP sequences in National Center for Biotechnology Information (NCBI) SNP database. Then real-time polymerase chain reaction (PCR) was conducted via TaKaRa Premix Ex Taq II Kit (TaKaRa Bio INC). According to the fluorescent color of probes melting curve analysis was used to define the genotyping of SNP and further analyzed by CFX Manager Software 1.6 software (Bio-Rad).

Statistical analysis was performed using SPSS20.0. Categorical variables were compared by the chi-squared test or Fisher’s exact test when appropriate. Continuous variables were tested for normal distribution using Kolmogorov-Smirnov test. Differences between two groups were assessed by Student’s T-test for parametric data and by the Mann Whitney U test for non-parametric data. Comparisons between values of more than two groups were evaluated by one-way analysis of variance (ANOVA) or Kruskal-Wallis test. Correlation between genotype frequencies and CAP risk was assessed by an adjusted odds ratio (OR) with 95% confidence interval (CI). The linkage disequilibrium among selected SNPs was estimated by calculating pairwise D’ and r2 statistics using Haploview (version 4.2; www.broad.mit.edu/mpg/haplovie). Haplotype analysis was also performed using this software. A difference was considered statistically significant when a p value < 0.05.

Results

Patient characteristics

The baseline characteristics of the study population are presented in Table 1. No significant differences between the two groups in terms of gender, age and common comorbidities (p > 0.05).
Table 1
Baseline characteristics of CAP patients and controls

|                          | CAP (n = 88) | Controls (n = 90) | p-value |
|--------------------------|-------------|------------------|---------|
| Sex                      |             |                  | 0.37    |
| Male                     | 41 (46.6)   | 48 (53.3)        |         |
| Female                   | 47 (53.4)   | 42 (46.7)        |         |
| Age, years               | 58.6 ± 12.9 | 56.9 ± 12.7      | 0.39    |
| Comorbidities            |             |                  |         |
| Diabetes                 | 12 (13.6)   | 10 (11.1)        | 0.65    |
| Hypertension             | 18 (20.5)   | 17 (18.9)        | 0.85    |
| Chronic heart disease    | 7 (8.0)     | 12 (13.3)        | 0.33    |

Values are presented as mean ± SD, median (range) or n (%).

Abbreviation: CAP, community-acquired pneumonia.

Associations between PTX3 SNPs and risk of CAP

The selected SNPs (rs2305619, rs38716527 and rs1840680) in this study were in Hardy-Weinberg equilibrium as shown in Table 2. The genotype frequency of rs1840680 AA was significantly different between CAP group and control group (p = 0.03). We detected a lower risk of CAP in individuals with rs1840680 AA homozygosity (OR = 0.32, 95% CI = 0.11–0.91, p < 0.05) (Table 2).
Table 2
Distribution of rs2305619, rs3816527 and rs1840680 SNP genotypes in CAP patients and controls

| SNP        | Genotype | CAP (n = 88) | Controls (n = 90) | OR (95% CI) | p-value |
|------------|----------|-------------|------------------|-------------|---------|
| rs2305619  | AA       | 12(13.6)    | 18(20.0)         | 0.60(0.25–1.42) | 0.24    |
|            | AG       | 36(40.9)    | 36(40.0)         | 0.90(0.47–1.72) | 0.75    |
|            | GG       | 40(45.5)    | 36(40.0)         | Reference    | -       |
| rs3816527  | AA       | 54(61.4)    | 53(58.9)         | 1.36(0.29–6.36) | 0.70    |
|            | AC       | 31(35.2)    | 33(36.7)         | 1.25(0.26–6.05) | 0.78    |
|            | CC       | 3(3.4)      | 4(4.4)           | Reference    | -       |
| rs1840680  | AA       | 6(6.8)      | 16(17.8)         | 0.32(0.11–0.91) | 0.03*   |
|            | AG       | 39(44.3)    | 37(41.1)         | 0.91(0.48–1.70) | 0.76    |
|            | GG       | 43(48.9)    | 37(41.1)         | Reference    | -       |

Values are presented as n (%). *p < 0.05.

Abbreviations: SNP, single nucleotide polymorphism; CAP, community-acquired pneumonia; OR, odds ratio; CI, confidence interval.

However, the allele frequencies of rs1840680 did not differ significantly between CAP group and control group (p > 0.05) (Table 3). In addition, no difference in genotype or allele frequency for rs2305619 and rs3816527 were observed between the two groups (p > 0.05). With respect to rs2305619 and rs3816527, no evidence of association with CAP risk was found (Table 3).

Table 3
Distribution of rs2305619, rs3816527 and rs1840680 SNP allele in CAP patients and controls

| SNP        | Allele | CAP (n = 88) | Controls (n = 90) | OR (95% CI) | p-value |
|------------|--------|-------------|------------------|-------------|---------|
| rs2305619  | A      | 60(34.1)    | 72(40)           | 1.29(0.84–1.98) | 0.25    |
|            | G      | 116(65.9)   | 108(60.0)        | Reference   | -       |
| rs3816527  | A      | 139(79.0)   | 139(77.2)        | 0.90(0.55–1.49) | 0.69    |
|            | C      | 37(21.0)    | 41(22.8)         | Reference   | -       |
| rs1840680  | A      | 51(29.0)    | 69(38.3)         | 1.50(0.98–2.37) | 0.06    |
|            | G      | 125(71.0)   | 111(61.7)        | Reference   | -       |

Values are presented as n (%).

Abbreviations: SNP, single nucleotide polymorphism; CAP, community-acquired pneumonia; OR, odds ratio; CI, confidence interval.

Haplotype analysis of PTX3 SNPs
The linkage disequilibrium (LD) among the three SNPs of PTX3 was analyzed using Haploview software. Our results showed that a strong linkage disequilibrium was detected between rs2305619, rs3816527 and rs1840680 (Fig. 1), and four haplotypes were constructed for them, namely AAA, AAG, ACA and GAG (Table 4). We compared haplotype distributions between CAP group and control group, while no haplotype was identified to be associated with CAP ($p > 0.05$).

| Haplotype | CAP | Controls | $p$-value |
|-----------|-----|----------|-----------|
| AAA       | 9.9 | 14.4     | 0.18      |
| AAG       | 5.7 | 4.6      | 0.62      |
| ACA       | 18.5| 21.0     | 0.54      |
| GAG       | 63.4| 57.1     | 0.23      |

Values are presented as Composition ratio. Those haplotypes whose distribution lower than 0.03 are ignored.

Abbreviations: CAP, community-acquired pneumonia

**Discussion**

In this study, we aimed to investigate whether the genetic variations of PTX3, including genotype, allele and haplotype frequency, is associated with CAP occurrence in Chinese adult patients. With respect to rs2305619, rs3816527 and rs1840680, we found that SNP rs1840680 AA homozygosity was associated with CAP occurrence. The AA variant of rs1840680 was related to a lower risk of developing CAP ($OR = 0.32$, $95\% CI = 0.11–0.91$, $p = 0.03$).

As a key player in innate immunity and inflammation, PTX3 plays an important role in the resistance to pathogens. Previous studies on the relationship between PTX3 and pulmonary bacterial infection have been mainly concentrated on *Pseudomonas aeruginosa* and *Streptococcus pneumoniae*. *P. aeruginosa* is one of the most common colonizers of the lung. PTX3 has potential therapeutic effects on chronic lung infections caused by *P. aeruginosa* [17]. According to a previous study in a mouse model infected with *P. aeruginosa*, PTX3 participated in the interaction between complements and Fcy receptors, significantly decreasing serum levels of pro-inflammatory cytokines (CXCL1, CXCL2, CCL2 and IL-1β) and reducing leukocyte recruitment of airway leukocytes [18]. GroEL in *P. aeruginosa* could induce PTX3 expression via NF-kB activation following signaling to Toll-like receptor 4 (TLR4), and GroEL-induced PTX3 promoted macrophage binding and phagocytosis of bacteria [19]. To notice, *S. pneumoniae* is the most frequent etiologic agent of community-acquired pneumonia in adults. Research findings demonstrated that *S. pneumoniae* infection could up-regulate the expression of PTX3 in vitro and experimental models. Hemolysin secreted by *S. pneumoniae* was involved in PTX3 expression and up-regulation through the JNK-MAPK signaling pathway [20].
According to previous findings, PTX3 SNPs (rs2305619, rs3816527 and rs1840680) were associated with various infectious diseases. PTX3 polymorphism is closely related to the occurrence of tuberculosis in the West African population, and haplotype GAG is considered to be a protective factor [12]. Another study focused on Caucasian patients with cystic fibrosis which demonstrated that haplotype GAG was also a protective factor for the development of *P. aeruginosa* colonization in the lungs [13]. In addition, He et al. reported that rs1840680 AA genotype might be a risk factor for developing fungal pulmonary infection in COPD patients [14]. Contrary to the findings of He et al., we found that patients with the AA genotype of rs1840680 had a lower risk of developing CAP. Because bacteria were the most common causative pathogens in CAP, we assume that the same genotype might play a different role during infection with fungi and bacteria.

Our findings suggest that the rs1840680 AA genotype might be a protective factor against the development of CAP in adults. The mechanism of PTX3 gene driven by infections in the process may involve protein expression, but the relationship between PTX3 SNPs and protein levels still remains controversial. We assume that rs1840680 AA genotype may up-regulate the expression of PTX3 when patients suffer from pulmonary bacterial infection. Some studies have found that rs1840680 AA genotype was associated with increased protein level in patients with primary liver cancer and acute myocardial infarction [21–22]. In patients with idiopathic pulmonary dysfunction after lung transplantation, PTX3 protein expression level was also increased carrying rs2305619 AA genotype [23]. However, in COPD patients with invasive pulmonary aspergillosis, compared to AG and GG genotype, rs1840680 AA genotype decreased the protein expression level [14]. These paradoxical findings may lead to pitfall of interpretation, thus further investigation in different populations is needed to confirm the role of this SNP variation.

We are aware of several limitations in our current study. Firstly, our study population reflected mild to moderate patients but not including severe pneumonia. Secondly, our study was conducted at a single medical center. Therefore, the sample size was relatively small and selection bias may have occurred. Moreover, etiological investigations were mostly negative in CAP patients from this study, so according to clinical manifestations and laboratory tests, we could only choose patients with most likely bacterial infection while exclude definite fungal diseases and active tuberculosis. In the future, we hope to gather more extensive data from multiple institutions and carry out functional studies to determine the identified SNP on the risk of CAP.

**Conclusions**

In summary, our results support that PTX3 polymorphisms were associated with the risk of CAP in Chinese adult patients. Individuals with SNP rs1840680 AA homozygote may have a lower risk of developing CAP. Further research is required to clarify the specific mechanisms.

**Abbreviations**
Declarations

Ethics approval and consent to participate:

This study has been approved by the Ethics Committee of Sun Yat-sen Memorial Hospital (number: SYSEC-KY-KS-2020-005).

Consent for publication:

Not applicable.

Availability of data and materials:

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests:

The authors declare that they have no competing interests.
Funding:

This work was supported by the National Natural Science Foundation of China [81670022]; the Guangzhou Municipal Science and Technology Project [201704020123]; and the Natural Science Foundation of Guangdong Province [2017A030313681].

Authors' contributions:

SPJ conceived and designed the study; TTT, LJH, QJZ, YQX, SYB, BRH, YMD, and ZXW had roles in clinical management and patient recruitment; YQX, SYB, YMD, BRH and ZXW contributed to data collections and data entry. YQX performed the statistics; TTT and YQX also performed the interpretation and manuscript writing. All authors reviewed and approved the final version of the manuscript.

Acknowledgements:

Not applicable.

References

1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG, Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2(Suppl 2):27–72.

2. Peyrani P, Arnold FW, Bordon J, Furmanek S, Luna CM, Cavallazzi R, Ramirez J. Incidence and Mortality of Adults Hospitalized with Community-Acquired Pneumonia According to Clinical Course. Chest. 2020;157(1):34–41.

3. Wunderink RG, Waterer GW, Cantor RM, Quasney MW. Tumor necrosis factor gene polymorphisms and the variable presentation and outcome of community-acquired pneumonia. Chest. 2002 Mar;121(3 Suppl):87S.

4. Wang X, Guo J, Wang Y, Xiao Y, Wang L, Hua S. Expression Levels of Interferon Regulatory Factor 5 (IRF5) and Related Inflammatory Cytokines Associated with Severity, Prognosis, and Causative Pathogen in Patients with Community-Acquired Pneumonia. Med Sci Monit. 2018;24:3620–30.

5. Chou SC, Ko HW, Lin YC. CRP/IL-6/IL-10 Single-Nucleotide Polymorphisms Correlate with the Susceptibility and Severity of Community-Acquired Pneumonia. Genet Test Mol Biomarkers. 2016;20(12):732–40.

6. Martín-Loeches I, Solé-Violán J, Rodríguez de Castro F, García-Laorden MI, Borderías L, Blanquer J, Rajas O, Briones ML, Aspa J, Herrera-Ramos E, Marcos-Ramos JA, Sologuren I, González-Quevedo N, Ferrer-Agüero JM, Noda J, Rodríguez-Gallego C. Variants at the promoter of the interleukin-6 gene are
associated with severity and outcome of pneumococcal community-acquired pneumonia. Intensive Care Med. 2012 Feb;38(2):256–62.

7. Mukamal KJ, Pai JK, O’Meara ES, Tracy RP, Psaty BM, Kuller LH, Newman AB, Yende S, Curhan GC, Siscovick DS, Rimm EB. CRP gene variation and risk of community-acquired pneumonia. Respirology. 2010;15(1):160–4.

8. Kunes P, Holubcova Z, Kolackova M, Krejsek J. Pentraxin 3 (PTX 3): an endogenous modulator of the inflammatory response. Mediators Inflamm. 2012;2012:920517.

9. Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol. 2008;28(1):1–13.

10. Sprong T, Peri G, Neeleman C, Mantovani A, Signorini S, van der Meer JW, van Deuren M. Pentraxin 3 and C-reactive protein in severe meningococcal disease. Shock;31(1):28–32.

11. Mauri T, Bellani G, Patroniti N, Coppadoro A, Peri G, Cuccovillo I, Cugno M, Iapichino G, Gattinoni L, Pesenti A, Mantovani A. Persisting high levels of plasma pentraxin 3 over the first days after severe sepsis and septic shock onset are associated with mortality. Intensive Care Med. 2010;36(4):621–9.

12. Olesen R, Wejse C, Velez DR, Bisseye C, Sodemann M, Aaby P, Rabna P, Worwui A, Chapman H, Diatta M, Adegbola RA, Hill PC, Østergaard L, Williams SM, Sirugo G. DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West Africans. Genes Immun. 2007;8(6):456–67.

13. Chiarini M, Sabelli C, Melotti P, Garlanda C, Savoldi G, Mazza C, Padoan R, Plebani A, Mantovani A, Notarangelo LD, Assael BM, Badolato R. PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients. Genes Immun. 2010;11(8):665–70.

14. He Q, Li H, Rui Y, Liu L, He B, Shi Y, Su X. Pentraxin 3 Gene Polymorphisms and Pulmonary Aspergillosis in Chronic Obstructive Pulmonary Disease Patients. Clin Infect Dis. 2018;66(2):261–7.

15. Cunha C, Aversa F, Lacerda JF, Busca A, Kurzai O, Grube M, Löffler J, Maertens JA, Bell AS, Inforzato A, Barbati E, Almeida B, Santos e Sousa P, Barbui A, Potenza L, Caira M, Rodrigues F, Salvatori G, Pagano L, Luppi M, Mantovani A, Velardi A, Romani L, Carvalho A. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med. 2014;370(5):421–32.

16. Cao B, Huang Y, She DY, Cheng QJ, Fan H, Tian XL, Xu JF, Zhang J, Chen Y, Shen N, Wang H, Jiang M, Zhang XY, Shi Y, He B, He LX, Liu YN, Qu JM. Diagnosis and treatment of community-acquired pneumonia in adults: 2016 clinical practice guidelines by the Chinese Thoracic Society, Chinese Medical Association. Clin Respir J. 2018;12(4):1320–60.

17. Moalli F, Paroni M, Véliz Rodriguez T, Riva F, Polentarutti N, Bottazzi B, Valentino S, Mantero S, Nebuloni M, Mantovani A, Bragonzi A, Garlanda C. The therapeutic potential of the humoral pattern recognition molecule PTX3 in chronic lung infection caused by Pseudomonas aeruginosa. J Immunol. 2011;186(9):5425–34.

18. Paroni M, Moalli F, Nebuloni M, Pasqualini F, Bonfield T, Nonis A, Mantovani A, Garlanda C, Bragonzi A. Response of CFTR-deficient mice to long-term chronic Pseudomonas aeruginosa infection and PTX3 therapy. J Infect Dis. 2013;208(1):130–8.
19. Shin H, Jeon J, Lee JH, Jin S, Ha UH. Pseudomonas aeruginosa GroEL Stimulates Production of PTX3 by Activating the NF-κB Pathway and Simultaneously Downregulating MicroRNA-9. Infect Immun. 2017;85(3):e00935-16.

20. Koh SH, Shin SG, Andrade MJ, Go RH, Park S, Woo CH, Lim JH. Long pentraxin PTX3 mediates acute inflammatory responses against pneumococcal infection. Biochem Biophys Res Commun. 2017;493(1):671–6.

21. Carmo RF, Aroucha D, Vasconcelos LR, Pereira LM, Moura P, Cavalcanti MS. Genetic variation in PTX3 and plasma levels associated with hepatocellular carcinoma in patients with HCV. J Viral Hepat. 2016;23(2):116–22.

22. Barbati E, Specchia C, Villella M, Rossi ML, Barlera S, Bottazzi B, Crociati L, d'Arienzo C, Fanelli R, Garlanda C, Gori F, Mango R, Mantovani A, Merla G, Nicolis EB, Pietri S, Presbitero P, Sudo Y, Villella A, Franzosi MG. Influence of pentraxin 3 (PTX3) genetic variants on myocardial infarction risk and PTX3 plasma levels. PLoS One. 2012;7(12):e53030.

23. Diamond JM, Meyer NJ, Feng R, Rushefski M, Lederer DJ, Kawut SM, Lee JC, Cantu E, Shah RJ, Lama VN, Bhorade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Weinacker A, Weill D, Arcasoy S, Shah PD, Belperio JA, Wilkes D, Ware LB, Palmer SM, Christie JD. Lung Transplant Outcomes Group. Variation in PTX3 is associated with primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med. 2012;186(6):546–52.

Figures
Figure 1

Linkage disequilibrium analyses for SNP genotype in the PTX3 gene region. (A) Shades of red indicated the strength of pairwise linkage disequilibrium based on $|D'|$, and numbers represent $|D'|$ expressed as a percentage. A value of $D'$ between SNPs > 0.8 indicate a linkage disequilibrium block. (B) Shades of pink indicated the strength of pairwise linkage disequilibrium based on $r^2$ and numbers represent $r^2$ expressed as a percentage.